Source: ERJ Open Res, 7 (3) 00194-2021; 10.1183/23120541.00194-2021
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Iris G.M. Schouten, Marise J. Kasteleyn, Roula Tsonaka, Robert Bals, Alice C. Turner, Ilaria Ferrarotti, Angelo G. Corsico, Beatriz Lara, Marc Miravitlles, Robert A. Stockley, Jan Stolk. Long-term effect of a₁-antitrypsin augmentation therapy on the decline of FEV₁ in deficient patients: an analysis of the AIR database. ERJ Open Res, 7 (3) 00194-2021; 10.1183/23120541.00194-2021

Member's Comments

No comment yet.

Related content which might interest you: Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients Source: Virtual Congress 2021 – Treatments for airway diseases Year: 2021 Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017 CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Annual FEV1% variation before and after augmentation therapy in severe alpha-1-antitrypsin deficiency Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019 Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Early ICS treatment in subjects with a rapid decline in lung function Source: Eur Respir J 2001; 18: Suppl. 33, 348s Year: 2001 A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo Source: Eur Respir J 2006; 28: Suppl. 50, 764s Year: 2006 Long-term predictors of lung function decrease in asthmatics: a 9 year follow-up study Source: Eur Respir J 2006; 28: Suppl. 50, 145s Year: 2006 Nasal high flow therapy: The effect on exercise performance in patients with COPD Source: International Congress 2018 – What’s new in lung function and exercise assessment in COPD? Year: 2018 CAPTAIN: Effects of lung function at screening (FEV1 % predicted) as a continuous variable on treatment outcomes Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Intermediate and severe α1-antitrypsin deficiency: influence on plasma α1-antitrypsin, FEV1 and risk of COPD. Three meta-anlyses Source: Eur Respir J 2002; 20: Suppl. 38, 513s Year: 2002 Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Inhaled corticosteroids and FEV1 decline in asthma: an international cohort study Source: International Congress 2018 – Asthma in children and adults: long-term aspects Year: 2018 FVC decline in patients with SSc-ILD by use of anti-acid therapy Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 =80% predicted Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021